Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs will be updated March 1, 2025:
Effective April 1, 2025:
- GLP-1 Agonists
- Insulin Combination Agents
- Insulin Pump
- Leqembi
- Long Acting Insulin
- Piasky
- Primary Biliary Cholangitis
- Pseudobulbar Affect
- Soliris Ultomiris
- VMAT2 Inhibitors
- Weight Management
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page.
If you have any questions please contact your BCBSKS provider representative.